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Abstract 
In this work, the capability of imaging biomarkers obtained from multivariate curve 
resolution-alternating least squares (MCR-ALS), in combination with those obtained 
from first and second-generation pharmacokinetic models, have been studied for 
improving prostate cancer tumor depiction using partial least squares-discriminant 
analysis (PLS-DA). The main goal of this work is to improve tissue classification 
properties selecting the best biomarkers in terms of prediction. A wrapped double cross-
validation method has been applied for the variable selection process. Using the best 
PLS-DA model, prostate tissues can be classified obtaining 13.4% of false negatives 
and 7.4% of false positives. Using MCR-ALS biomarkers yields the best models in 




Angiogenesis and neovascularization are biological processes associated to tissues with 
increased oxygen and nutrient demand. These processes seldom occur in healthy 
subjects, but they are strongly present in pathological conditions such as tumors. The 
formation of these new and tortuous vessels produces an increase in the blood 
perfusion, which can be studied with dynamic contrast-enhanced Magnetic Resonance 
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imaging (DCE-MRI) [1]. In DCE-MRI studies, an exogenous contrast media is 
administered intravenously and diffuses from the capillary network into the 
extravascular extracellular space (EES) and return, establishing a dynamic relationship 
between the image signal intensity changes and the amount of contrast media that 
passes and diffuses into a certain tissue. The capability to analyse tumor angiogenesis in 
a quantitative and reproducible way from DCE-MR images has important applications 
to depict and gradate tumors, and also to evaluate the therapeutic response early after 
treatment onset [2, 3]. To obtain quantitative measurements, it is necessary to fit and 
characterize the intensity versus time curves associated to each voxel of the image. Out 
of the different approaches proposed to achieve this characterization, mathematical 
pharmacokinetic models have become the most popular way due to their ability to 
provide clinically-oriented biomarkers in tumor analysis. Nevertheless, new biomarkers 
obtained from multivariate curve resolution (MCR) models have recently been also 
proposed [4-6]. 
The aim of this work is to make a model comparison between different imaging 
perfusion related biomarkers, selecting the more relevant ones in terms of tumor 
prediction in order to reduce the false negatives and false positives rates (the negatives 
and positives corresponds to healthy and tumoral defined tissue respectively), thus 
improving the tissue classification. The paper is organised as follows. In Section 2 the 
type of images used and the pharmacokinetic and MCR models analysed are introduced. 
Section 3 presents the results of the statistical comparison performed with classification 
methods such as PLS-DA and discusses the pros and cons of using the different types of 
biomarkers studied. Finally, Section 4 provides the conclusions. 
2. Material and Methods 
 
The database consists of 30 histologically-confirmed cases of peripheral prostate 
tumors. DCE-MRI sequences are acquired in all cases, ensuring full prostate coverage 
(12 slices) by using an in-plane resolution of 192  192 voxels, each one measuring 
1.5625  1.5625  4 mm3, and 47 time points (acquisition time 5 minutes). Data are 
arranged in a 3D matrix (192  192  47) for each slice. Also, reference tumor and 
control normal region of interest (ROIs) have been manually segmented for the 
peripheral zone of the prostate, considering biopsy location and image findings, using a 
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structured reporting scheme for evaluating prostate cancer known as Prostate Imaging – 
Reporting and Data System (PI-RADS) version 2 [7]. This scale ranges from 1 to 5, 
based on increased tumor aggressiveness, and allows defining two different types of 
ROIs: 
 
 DL: Dominant Lesion, related to carcinogen tissue at the peripheral prostate 
zone (PI-RADS ≥ 4). 
 HP: Healthy Peripheral, related to healthy tissue at the peripheral prostate zone 
(PI-RADS=1). 
These ROIs are manually defined by radiologists, considering the PI-RADS score and 
the biopsy result, and are used as the gold reference for tissue classification.  
It is assumed that the behaviour of the healthy regions on the peripheral zone of the 
gland has no significant differences between cancer and healthy patients [8]. Therefore, 
it could be used safely as the healthy tissue reference. 
All patients gave consent for using their medical images, which were anonymized 
before post-processing. 
2.1. Pharmacokinetic models calculation 
 
In radiology, pharmacokinetic models try to characterize the absorption, distribution 
and excretion dynamics followed by some tissue when injecting a contrast agent. In this 
work, compartmental models have been used to describe tissue dynamics, considering 
the intravascular and the extracellular extravascular (EES) spaces as main 
compartments. Four different models are considered, divided into two groups according 
to its complexity. On the one hand, “classical” or “first-generation” models, considering 
the Tofts model, and on the other hand “second-generation” models, 2CXM (2-
compartment exchange model), AATH (adiabatic approximation to tissue homogeneity) 
and DP (distributed parameter) [9]. 
 
Tofts et al. [9] firstly introduced a one-compartment model as a generalization of the 





= Ktrans · CAIF(t) − kep · Ct(t)  EES mass balance (eq.1) 
 
Where Ktrans (min-1) is the volume transfer constant; kep (min
-1) is the washout constant; 
CAIF (mg/ml) is the contrast concentration of the arterial input function (AIF), which 
describes the contrast agent input to the tissue of interest; and Ct (mg/ml) is the contrast 
concentration in the EES. 
 
This model assumes that the effect of the vascular tracer can be ignored. Ktrans 
represents the total contrast transference from the plasma space to the EES, whereas kep 
is associated with the washout of the contrast from the EES to the plasma. In this case, 
the tracer transport is modelled through the EES compartment with normalized volume 
(ve=K
trans/kep). This model is known as “first-generation” pharmacokinetic model and 
have been widely applied in oncology for perfusion analysis till the present days. 
However, the development and evolution of MRI hardware has provided an 
improvement in image quality and pixel resolution that exposes the limitations of the 
classical models. This allows developing new approaches designed to overcome the 
limitations of ‘classical’ models to obtain additional and more accurate information 
about the tissue. The most important models are the 2CXM, AATH and the DP model 
[9]. These new approaches are known as “second-generation” models and a scheme is 
shown in Figure 1. 
[INSERT FIG. 1 ABOUT HERE] 
 
The main advantage of second-generation models is the possibility of measuring the 
plasma flow (Fp) separately from the capillary permeability-surface area product (PS) 
rather than a single parameter (Ktrans), whose physiological meaning represents a 
combination of Fp and PS. The separation of both phenomena allows a better 
understanding of perfusion behaviours in tumors. 
Second-generation models are bicompartmental. In this way, the EES (ve) and plasma 
space (vp) can be used undivided or be further divided into infinitesimal 
subcompartments according to the model scheme (Figure 1). The notation is defined as 
follows: vp (ml/ml) is the normalized volume of the plasma space; ve (ml/ml) is the 
normalized volume of the EES; Cp (mg/ml) is the contrast concentration in the plasma 
space; Ce (mg/ml) is the contrast concentration in the EES; Fp (min
-1) is the plasma flow; 
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PS (min-1) is the permeability-surface area product; E (%) is the extraction fraction; and 
L (mm) is the distance between the first and last subspace. 
 
In the same way as the Tofts model, mass balances can be applied to the different 
compartments for tissue modelling, depending on the corresponding complexity. 2CXM 









(t) = PS · Cp(t) − PS · Ce(t)  EES balance (eq.3) 
 
The next one is the AATH model, where the plasma space is divided in infinitesimal 
subcompartments and it is assumed that the permeability contrast transference is 






(x, t) = −Fp
∂Cp
∂x




(t) = E · Fp · Cp(L, t) − E · Fp · Ce(t)  EES balance (eq. 5) 
 
Finally, in the DP model both compartments are divided into infinitesimal spaces and 


























Ce(x, t)  EES subspace balance (eq. 7) 
 
These systems of partial differential equations have been already solved and the contrast 
concentration C(t) can be expressed as a convolution product of the CAIF and the R(t) 
function, which is the solution of the mass balances. These contrast concentrations are 
directly related with the DCE-MRI signal intensity. In this work, C(t) has been obtained 
from I(t) using a direct conversion based on relaxivity and field strength, being I(t) the 
signal intensity of each pixel at each time point. 
 
C(t) = (CAIF ∗ R)(t)     (eq. 8) 
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In this expression, R(t) only depends on the first (Ktrans, kep, ve) or second (Fp, PS, ve, 
vp) generation perfusion biomarkers at each time instant (t). In order to obtain these 
biomarkers, the models need as input the reference arterial input function (CAIF), which 
has been calculated in this work using a PCA model [10], selecting the voxels related to 
the arterial dynamic pattern [11]. Once the CAIF is calculated for each patient 
individually, the perfusion sequence is analysed voxel-by-voxel applying the different 
pharmacokinetic approximations. 
 
The biomarkers are calculated using non-linear optimization algorithms. For this 
purpose, the values of these biomarkers are evaluated in order to minimize, for each 
model at each voxel, the difference between the contrast measured concentration and 
the convolution product function: (CAIF * R) (t). Note that non-linear optimization can 
only provide local optimums. In order to obtain reliable results, the optimization method 
defines different starting points and selects the best result minimizing the Residual Sum 
of Squares (RSS) evaluated as the sum of the squared differences at each time point. 
Using this technique, the probability of obtaining the global optimum is higher as the 
number of starting points increases, testing a relatively high number of “starting points” 
in the variable space. 
 
Following the previous method, 3 biomarkers are obtained in the case of the Tofts 
model (Ktrans, kep, ve) and 4 when considering second-generation models (Fp, PS, ve, vp). 
It must be strengthened, however, that these pharmacokinetic models assume some a 
priori knowledge about the dynamics followed by the tissues. Nevertheless, it is 
possible that, when the tissue starts producing new vessels and tissue structures in a 
chaotic way, the dynamics do not behave as expected. Therefore, this work proposes to 
use, not only these biomarkers, but also the RSS as a complementary biomarker, which 
would provide information about how well the voxel is fitted by the assumed model. 
Figure 2 shows the biomarker images obtained from an example of the AATH model 
calculated for a specific slice of a tumoral affected patient. 
 




2.2. MCR-ALS models calculation 
 
One characteristic of the pharmacokinetic models is the lack of a priori knowledge 
about the tissue vascular environment, which leads to a series of assumptions 
conditioning the use of different approaches [12]. Accordingly, and depending on the 
tissue dynamics patterns, the pharmacokinetic models may provide biased 
measurements, which may not properly reflect the true physiology of the tissue [13]. 
Therefore, a priori knowledge about the tissue dynamics might help interpreting the 
information provided by the pharmacokinetic parameters. 
One possible way to look for physiological meaningful dynamics is by applying 
multivariate statistical projection models to the DCE-MRI data. When dealing with 
images, the application of these models is known as Multivariate Image Analysis (MIA) 
[14, 15], usually based on the principal component analysis (PCA) [10]. Its application 
to oncology [16] allows extracting the sources of variation from a relevant number of 
time-sequenced images from different individuals, providing new statistical models that 
help explaining the perfusion differences between healthy tissues and tumors. 
Nevertheless, a relevant drawback of the application of PCA in DCE-MR image 
analysis is that the estimated dynamics patterns are orthogonal by design. The 
orthogonality of the principal components is a limitation to model different perfusion 
behaviors that are not necessarily orthogonal. In order to overcome these drawbacks, it 
is possible to use more flexible models as Multivariate Curve Resolution-Alternating 
Least Squares (MCR-ALS) [17, 18], which do not impose this restriction. MCR is 
preferred to PCA because of its ability to provide physiologically more interpretable 
behaviors by imposing a priori knowledge on the model. MCR-ALS is an iterative 
method that performs a bilinear decomposition of an S matrix by means of an 
alternating least squares optimization algorithm,  
𝐒 = 𝐂𝐃𝐓 + 𝐄     (eq. 9) 
 
Where S contains the signal intensity registered for each voxel in rows; DT is a matrix 
containing in its rows each of the dynamic habits modelled (figure 4); C gathers in its 
rows the relative contribution of each modelled for each voxel of the image; and E is a 
residual matrix [4-6].  
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As commented in Section 2, for each slice of the studied tissue in each patient, DCE-
MR images are arranged as a 3D data volume constituted by 2D images obtained at 
each time point t. The S matrix is constructed by reshaping the slices one-by-one (i.e. 47 
images per slice) in a bidimensional matrix where the rows are the voxels and the 
columns are the time points. Thus, in this case the S dimensions are ((n1  n2) x 47) 
where n1  n2 is the image resolution. Then, the global S matrix (per patient) is built 
stacking all the slices column-wise. A schema about the dimensions of the matrices in 
equation 9 is shown in figure 3. 
[INSERT FIG. 3 ABOUT HERE] 
 
By refolding the C matrix into the original spatial dimensions, new biomarker images 
are obtained (figure 5), which allow locating those voxels more related to each one of 
the corresponding modelled dynamic behaviors. In this case, equal length normalization 
is applied for DT matrix during the MCR-ALS iterative process in order to obtain 
concentration C that can be directly compared between them. 
 
The process of obtaining the number of components and the initial estimation of DT 
matrix is described in previous works [4,6]. According to these works, two components 
are considered in MCR models regarding to the dynamic patterns related to perfusion 
studies that can be expected using the a priori knowledge about the process. (i.e. normal 
tissue (type NT) and vascular tissue (type VT) (figure 4). Also, a third component is 
obtained because of the appearance of an artefact introduced by the equipment defined 
as CMA [4,6]]. However, this component is not included on this work because it is a 
non-informative parameter for tumor classification. The NT and VT are the dynamic 
behaviors that we should expect when studying perfusion. They correspond to how a 
non-affected and vascularized tissue should behave respectively. When MCR is applied 
on different patients we found few variations among them, but they are essentially the 
same dynamic behaviors in terms of interpretation. Moreover, also in this case, it is 
possible to include the RSS of the MCR model as an additional potential biomarker 
measuring the lack of fit in each voxel location (Figure 5). 
 
[INSERT FIG. 4 ABOUT HERE] 
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[INSERT FIG. 5 ABOUT HERE] 
 
MCR-ALS is based on an iterative process that can provide infinite solutions for the 
same data matrix causing a problem known as ambiguity in the solution. This problem 
can be solved by imposing constraints commonly related to prior knowledge about the 
problem faced, so that it is possible to obtain easier-to-interpret solutions, which also 
tend to be unique when constraints introduced under the hypothesized assumptions are 
sensible. 
For this, two additional constraints were imposed:  
 Non-negativity on the pixel concentration C values, because the intensity in a 
pixel has to be nonnegative. 
 
 Non-negativity on the dynamics profiles DT.   
Besides, equal length normalization is applied to DT matrix during the MCR-ALS 
iterative process in order to obtain concentrations C that can be directly compared 
between them. 
The ambiguity in the solution problem has been checked in previous works through 
MCR-bands [4]. In this paper the tuned bands were very close to the proposed solution 
and the dynamic habits found can be considered unambiguous. 
2.3. Variable selection using double cross-validation (2CV) with 
PLS-DA 
 
In this work, the capability of imaging biomarkers obtained from multivariate statistic 
methods in combination with biomarkers from second-generation pharmacokinetic 
models have been studied and compared for improving prostate tissue classification 
using statistical classification methods based on latent structures, such as partial least 
squares-discriminant analysis (PLS-DA) [19, 20].  
Firstly, the input matrices (X, Y) for the PLS-DA model have been built using the 
biomarker images obtained from the different approximations, i.e. pharmacokinetic or 
MCR models. The X matrix is constructed by stacking all the selected voxels in rows 
with the value of the different considered biomarkers in columns. The selected voxels 
are the ones defined by the radiologists as DL (lesion) or HP (healthy) ROI’s for each 
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patient. These ROI’s are logical images associated to one specific slice of the prostate. 
Thus, the X matrix is constructed by stacking all the voxels assigned at the 
corresponding local image for all the patients. For the same voxels, a 2-column Y 
matrix is defined with two dummy variables (0-1). The first column defined the “DL” 
variable (value 1 if the voxel belonged to the “DL” region and value 0 if otherwise). 
The second column defined the “HP” variable and is built complementary to the first 
one. From this model, the class showing higher value is assigned to the corresponding 
voxel. Using the PLS-DA model predictions, the assigned category of the voxels has 
been compared with the original classification. Therefore, if the voxel belongs to HP, it 
can be evaluated as a TN (True Negative) or FP (False Positive) depending on the 
prediction, and as a TP (True Positive) or FN (False Negative) if it is DL. Then, two 









    (eq .10) 
 
Both indexes are combined in a new performance index, f-score, chosen to evaluate the 
classification model performance. The f-score [19] is defined as the weighted harmonic 





    (eq. 11) 
 
This parameter determines the goodness of prediction for a classification model. It 
ranges between 0 and 1, and takes the maximum when the precision and recall are one 
(the number of FP and FN are zero). The closer the f-score is to one, the better the 
model is in terms of prediction. 
 
The variable selection method proposed in this work (Figure 6) is a wrapped double 
cross-validation (2CV) with variable selection, showing high similarities with other 
2CV methods [21, 22]. This methodology is applied in order to determine which 
parameters supply relevant information for classification. In this work, the variable 
selection method allows us to remove all non-informative variables improving the 
classification performance (misclassifications rate based on the f-score).  
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The method consists of dividing the voxels from the cases of the data set (30 patients in 
this work) in three randomized groups of cases (i.e. 10 patients), defined as training, 
validation and test. All the voxels from each case have their own class identification 
(DL or HP) and are located in their corresponding group. This way, the voxels from a 
specific case are always included in the same group in order to avoid any type of 
overfitting. Moreover, the number of voxels in each category has been balanced as 
much as possible in order to avoid any bias of the model. 
 
The method performs as follows: starting from a number of latent variables (NLV) 
equal to one, the training set is used for PLS-DA model building, using all the variables 
(biomarkers) of the considered pharmacokinetic or MCR model. Then, projecting the 
validation set onto the model fitted with the training set, an initial f-score (0) is 
calculated evaluating the performance in the model classification. 
 
The f-score (0) is stored and then, the values of the BPLS coefficients for each variable or 
biomarker are compared with their “null” distribution obtained after breaking the 
correlation structure between X and Y of the training set. This breakage process consists 
of randomizing the order of the Y matrix rows keeping the same X and building a PLS-
DA model to obtain the “null” model coefficients. This is internally repeated 500 times 
in order to obtain the null distribution [21, 22] of these coefficients. This way, the 
variable (biomarker) is removed from the X matrix if the coefficient of a certain 
variable is not statistically significant. It is considered statistically significant if the real 
coefficient is out of the central 95% range for the random null distribution values (i.e. 
=0.05).  
 
Once all the non-statistically significant variables are removed, a new PLS-DA model is 
built with the remaining significant variables from the training set X matrix, obtaining a 
new value of f-score (1) after projecting again the same validation set (only using the 
remaining significant variables) onto the new PLS-DA model. If the new f-score (1) is 
higher than f-score (0), the model is improved and the new value of f-score (1) is 
updated. In this case, the iterative process continues with a new variable selection 
comparing the new BPLS coefficients after breaking again the correlation structure 
between X and Y. However, if f-score (1) is lower than f-score (0), the best model is the 
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one considered in the previous step. This iterative process is repeated until the f-score 
(n) is lower than the one obtained in the previous step, f-score (n-1); keeping this “best” 
model with its associated f-score (n-1) and its own variable selection. From the best 
model selected, a final external set (test) is projected onto this model obtaining the 
“final f-score”. This value is stored for further comparisons.  
 
Afterwards, the NLV is increased in one repeating the same process explained for one 
NLV. This way, at the end we obtain N-1 (where N is the initial number of variables 
considered in the X matrix) improved models (with its own variable selection) and with 
their associated value of NLV and final f-score. After this, the final f-score of these N-1 
models are compared and the highest final f-score determines the best model with the 
best variable selection. Note that if different models provide the same value of final f-
score, the most parsimonious model is preferred for simplicity. 
 
Once this process is completed, the initial groups (training, validation and set) are 
permuted (P) in the three possible different combinations (i.e. training to validation, 
validation to test and test to training) ensuring that every case belonged, at least, one 
time to each group. Then the iterative process is repeated again with the new groups, 
obtaining, at the end, three different improved models. Finally, the initial group 
randomization is repeated 500 times obtaining (500 x 3 = 1500) different data 
organizations. This scheme is shown in Figure 6. 
 
[INSERT FIG. 6 ABOUT HERE] 
 
At the end of the process, the value of the final f-score, the variable selection 
(biomarkers that remain in the model), the percentage of TN, TP, FN, FP and the related 
NLV for this “best” model obtained for each distribution of the groups (1500) are 
stored.  
 
Once the process is finished, the variable relative inclusion rate (percentage of times a 
variable is included from a pharmacokinetic, MCR or combined model) is evaluated as 
an additional indicator. 
In order to show summarized and consistent results, the analysis is simplified selecting 
the highest 5% final f-score models. Also, as an additional constraint for this “5% 
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selection”, the percentage of FN is limited to 20%, considering a higher percentage 
excessive for tumor detection. 
 
All calculations are performed in Matlab R2014b (The Mathworks Inc., Natick, MA, 
USA). 
 
3. Results and Discussion 
 
The pharmacokinetic and MCR models have been evaluated, individually and in 
combination, in order to improve the results with different types of biomarkers. This 
way, the number of columns of the X matrix may vary depending on the number of 
biomarkers of the selected models. Table 1 shows the results: 
 
[INSERT TABLE 1 ABOUT HERE] 
 
Three one-way ANOVAs have been proposed to study the statistical effect of the model 
on f-score, %FP and %FN by means of the Least Significant Difference (LSD) Intervals 
(Figures 7, 8 and 9), respectively. 
 
[INSERT FIG. 7 ABOUT HERE] 
 
[INSERT FIG. 8 ABOUT HERE] 
 
[INSERT FIG. 9 ABOUT HERE] 
 
As can be seen in the figures, statistical significant differences are observed between the 
proposed models for the mean f-score and %FP (Figures 7 and 8). However, no 
statistically significant differences appear between FN rates, as can be seen in Figure 9. 
Therefore, the ANOVA analyses show that the differences between the f-score are due 
to the differences in the %FP. Regarding the f-score and %FP, Toft’s model (mean f-
score of 0.73 and mean %FP of 20.7) performs significantly worse than two of the 
second-generation models (AATH and 2CXM) because their LSD intervals do not 
overlap obtaining, a mean f-score of 0.755 and a mean %FP of 15.4 . Furthermore, 
second-generation 2CXM or AATH models are preferred over DP models due to the 
excessive computational time required to obtain the DP biomarkers, much higher than 
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the other two second-generation models (6 times longer per voxel). Nevertheless, MCR 
alone or in combination with the best pharmacokinetic models obtained the best results 
for prediction, significantly better than any other types of model. This way, the mean f-
score raised up to 0.7857 with 0.8145 as its maximum value, heavily reducing the rate 
of false positives (from 15.4% to 7.4%), which corresponds with 0.74 of sensitivity and 
0.85 of specificity. These results are better than other studies including only first 
generation pharmacokinetic models [8, 23-26]. Additionally, no statistically significant 
differences were observed between the MCR and combined models. This suggests that 
using just MCR can be considered the best option for improving the f-score, since it is 
the most parsimonious model (i.e. adding the second-generation biomarkers do not 
improve statistically the classification results). 
 
Regarding the variable inclusion rate in the combined models, the MCR-ALS and the 
pharmacokinetic RSS variables have been included in more than 90% of the times, a 
much higher percentage in comparison with the 70% inclusion rate of the 
pharmacokinetic biomarkers. This result suggests that voxels that do not fit the models 
properly (high RSS) should be considered as potential locations for abnormal vascular 
behaviors. They could be related to the presence of a tumor, and could be used as a 
surrogate indicator in order to locate lesions (i.e. a new biomarker). This finding needs 
further validation. Additionaly, the RSS parameter can be used as an indicator of how 
reliable the provided pharmacokinetic biomarkers are. This way, voxels that are not 
well fitted by the model could be re-estimated by using imputation methods [27]. 
 
This study has some limitations. The classification index (f-score) parameter was 
selected because it is a balanced combination of the parameters that need to be 
minimized for improving the classification goodness (rates of FN and FP), but other 
indexes can be used instead (e.g. AUROC, area under the receiver operating 
characteristic curve, a common quality index in medicine). Both parameters are used in 
the field [28-30] and provide equivalent information. However, f-score is preferred in 
this work due to its simplicity and independence from the number of TN (the 
comparison of both figures-of-merit is out of the scope of this work). Also, the method 
proposed in this work is a combination of 2CV with variable selection, and could be 
tested by comparing the results with other variable selection methods (e.g. VIP’s, 
LASSO or selectivity ratio) [31-33]. Therefore, this work can be complemented making 
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a comparison between different methods and indexes for selecting the one that provides 




Out of the pharmacokinetic models proposed, AATH has showed up as the best one, 
whereas the DP model is discarded due to the high computational time, and 2CXM is 
less consistent in comparison with AATH. These second-generation models have 
performed better for tumor detection than classical Tofts models, as demonstrated by 
the higher values of f-score. Also, RSS has risen as a potential biomarker in terms of 
inclusion rate. 
 
Nevertheless, the use of imaging biomarkers from MCR-ALS methods has provided 
better results than the DCE-MRI pharmacokinetic approximations for voxelwise 
classification. The MCR dynamic behaviours (NT and VT) and the RSS were most of 
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Table 1. Results summary for each considered model or models combinations using the 
5% best models according to the final f-score. The best biomarkers were selected in 












TOFTS 0.7871 0.7302 20.7 14.6 
RSS, ve (80%) 
Others (<60%) 
AATH 0.8125 0.7530 16.8 13.2 
RSS (95%) 
Others (80%) 
2CXM 0.8187 0.7556 15.4 13.6 
Fp RSS (90%) 
Others (50-60%) 
DP 0.8318 0.7455 16.1 14.7 
RSS (100%) 
Others (<60%) 
MCR 0.8145 0.7857 7.5 13.5 
Type VT (95%) 









0.8388 0.7804 9.6 12.6 
MCR (>90%) 
AATH (60-70%) 
MCR +  
DP 
0.8659 0.7725 10.1 13.8 
MCR (>90%) 
DP (60-70%) 




Figure 1. Second-generation models scheme, (left to right: two-compartment exchange 
model, 2CXM; adiabatic approximation of tissue-homogeneity, AATH; distributed-
parameter, DP) sorted in terms of complexity attending to the number of compartmental 
divisions. 
Figure 2. AATH model biomarker images representing the value of FP, PS, ve and vp, 
calculated voxel-by-voxel. The residual sum of squares (RSS) biomarker image is 
included as a new biomarker type, showing the lack of fit in each voxel. 
Figure 3. MCR model schema containing the dimensions of the matrices for the DCE-
MRI perfusion analysis. The 3 components considered in this model are the ones related 
to NT (normal tissue), VT (vascularized tissue) and CMA (contrast media arrival). 
Figure 4. Dynamic behaviors obtained from MCR-ALS model, representing VT 
(vascularized tissue) and NT (normal tissue). 
 
Figure 5. MCR-ALS biomarker images representing the relative contribution of each 
dynamic behavior (vascularized tissue VT and normal tissue NT) to a specific voxel. 
The residual sum of squares (RSS) distribution map shows the voxels that are not well 
fitted by the model. 
Figure 6. Variable selection process scheme, repeated 500 times to obtain the results for 
each proposed model. P represents the number of the three different group permutations 
proposed and NLV is the number of latent variables for PLS-DA. 
Figure 7. LSD ANOVA intervals for the f-score mean of the different individual and 
combined models (=0.05) separated by the black dotted line. 
Figure 8. LSD ANOVA intervals for the %FP mean of the different individual and 
combined models (=0.05) separated by the black dotted line. 
Figure 9. LSD ANOVA intervals for the %FN mean of the different individual and 
combined models (=0.05) separated by the black dotted line. 
